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Research
AbstrACt
Objectives To assess the long-term cost-effectiveness 
of insulin pumps and Dose Adjustment for Normal Eating 
(pumps+DAFNE) compared with multiple daily insulin 
injections and DAFNE (MDI+DAFNE) for adults with type 1 
diabetes mellitus (T1DM) in the UK.
Methods We undertook a cost–utility analysis using the 
Sheffield Type 1 Diabetes Policy Model and data from the 
Relative Effectiveness of Pumps over Structured Education 
(REPOSE) trial to estimate the lifetime incidence of diabetic 
complications, intervention-based resource use and 
associated effects on costs and quality-adjusted life years 
(QALYs). All economic analyses took a National Health Service 
and personal social services perspective and discounted 
costs and QALYs at 3.5% per annum. A probabilistic 
sensitivity analysis was performed on the base case. Further 
uncertainties in the cost of pumps and the evidence used to 
inform the model were explored using scenario analyses.
setting Eight diabetes centres in England and Scotland.
Participants Adults with T1DM who were eligible to 
receive a structured education course and did not have a 
strong clinical indication or a preference for a pump.
Intervention Pumps+DAFNE.
Comparator MDI+DAFNE.
Main outcome measures Incremental costs, incremental 
QALYs gained and incremental cost-effectiveness ratios 
(ICERs).
results Compared with MDI+DAFNE, pumps+DAFNE 
was associated with an incremental discounted lifetime 
cost of +£18 853 (95% CI £6175 to £31 645) and a gain 
in discounted lifetime QALYs of +0.13 (95% CI −0.70 
to +0.96). The base case mean ICER was £142 195 per 
QALY gained. The probability of pump+DAFNE being cost-
effective using a cost-effectiveness threshold of £20 000 
per QALY gained was 14.0%. All scenario and subgroup 
analyses examined indicated that the ICER was unlikely to 
fall below £30 000 per QALY gained.
Conclusions Our analysis of the REPOSE data suggests 
that routine use of pumps in adults without an immediate 
clinical need for a pump, as identified by National Institute 
for Health and Care Excellence, would not be cost-
effective.
trial registration number ISRCTN61215213.
strengths and limitations of this study
 ► This study is the first cost-effectiveness analysis to 
consider the use of insulin pumps for adults with 
type 1 diabetes who are eligible to receive struc-
tured education course but not an insulin pump us-
ing current UK guidance.
 ► The Relative Effectiveness of Pumps over Structured 
Education (REPOSE) trial was the first trial to address 
the question of whether insulin pumps were a clin-
ically effective treatment option in this population.
 ► An existing validated model of type 1 diabetes and its 
complications, developed during a previous National 
Institute for Health Research funded programme 
grant, was adapted and updated with evidence from 
the REPOSE trial and more recent evidence on clini-
cal effectiveness, utilities and costs.
 ► We considered a UK healthcare perspective to esti-
mate the key drivers of decision uncertainty.
 ► The main limitations of the study are that the only 
available evidence in long-term trends in HbA1c (the 
key clinical outcome) was from several observation-
al studies, the analysis of diabetic ketoacidosis was 
based on self-reported information rather than data 
from inpatient admissions and that the trial only in-
cluded one type of insulin pump.
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IntrOduCtIOn  
People with type 1 diabetes mellitus (T1DM) are unable 
to produce insulin due to autoimmune destruction of 
their insulin-secreting beta cells. Those affected have to 
inject insulin to prevent diabetic ketoacidosis (DKA) in 
the short term, and in the long term, to prevent micro-
vascular and macrovascular disease. Insulin is generally 
administered by intermittent subcutaneous injection with 
the dose adjusted according to eating, physical activity and 
current blood glucose levels. Therapy is designed to keep 
blood glucose as close to normal as possible, to prevent 
both microvascular complications and to reduce the risk 
of macrovascular disease.1 A further aim of treatment is 
to achieve as good a quality of life as possible, particularly 
since self-management of the condition is challenging and 
arduous, demanding the implementation of complex skills.
Historically, insulin was given twice a day, often as 
premixed insulin, but such an approach imposes a 
rigid lifestyle on people with T1DM and makes it diffi-
cult to maintain blood glucose levels close to normal. 
Most individuals require intensive insulin therapy to 
maintain tight glycaemic control. This approach and 
its integration within a flexible lifestyle is promoted in 
structured training courses, such as the Dose Adjust-
ment For Normal Eating (DAFNE)2 course and others.3 
The principles of this multiple daily injections (MDI) 
via subcutaneous injection approach involves the use 
of quick-acting insulin injected before eating (with the 
dose calculated according to the amount of carbohydrate 
eaten) combined with long-acting background ‘basal’ 
insulin, usually given twice daily, to control blood glucose 
in between meals.
As an alternative to MDI, insulin can be administered 
by an insulin pump system in which insulin is delivered 
throughout the day using a small, portable pump, connected 
by a flexible plastic tube to a subcutaneous cannula. This 
technology is relatively expensive compared with MDI. 
Current National Institute for Health and Care Excellence 
(NICE) guidelines recommend that all adults with T1DM 
in the UK receive a structured education course of proven 
benefit at a clinically appropriate time.4 Insulin pumps are 
a treatment option for adults with T1DM who either have a 
HbA1c above 69 mmol/mol (8.5%) or experience disabling 
hypoglycaemia.5 Insulin pumps do not replace the need for 
education, and it is currently recommended that specialist 
teams should provide structured education programmes 
and advice on diet, lifestyle and exercise for people using 
an insulin pump.5
Use of pumps in T1DM varies substantially between 
countries. In England, 11.7% of people with T1DM are 
estimated to use a pump, which compares to around 40% 
in the USA.6 7 It has been proposed that insulin pumps are 
underused in the UK and that the glycaemic control of 
adults with T1DM could be improved if pumps were used 
more widely.8 Two NICE appraisals found that there was 
insufficient evidence on insulin pump therapy compared 
with MDI in which adults with T1DM used both long-
acting and short-acting insulins.9 10 Furthermore, a recent 
observational study of pumps and MDI suggested that 
much of the previous benefit attributed to pumps may be 
due to the additional education that pumps users require 
when initiating therapy.11 Therefore, uncertainty remains 
as to the clinical benefit and cost-effectiveness of pumps 
as a treatment option for adults with T1DM.
The Relative Effectiveness of Pumps over Structured 
Education (REPOSE) trial was conducted to assess if pumps 
offered any additional benefit compared with MDI for the 
treatment of adults with T1DM in the UK who are eligible 
to attend a structured education course but do not have an 
immediate clinical need for a pump. Participants in both 
trial arms received a DAFNE course, which taught MDI 
users to use long-acting and short-acting insulins appropri-
ately. In this paper, we present the cost-effectiveness analysis 
of pumps+DAFNE compared with MDI+DAFNE for adults 
in the UK with T1DM who are eligible to receive a struc-
tured education course but did not have a clinical need for 
the immediate commencement of pump therapy.
MethOds
economic evaluation methods
The health economic analysis followed the prespecified 
health economic analysis plan, which was outlined in the 
trial protocol paper.12 Two approaches were undertaken 
to assess the cost-effectiveness of pumps: an economic 
evaluation alongside the clinical trial (EEACT) and a long-
term economic model to assess the lifetime outcomes. 
In the EEACT, data on the costs and quality-adjusted 
life years (QALYs) were obtained from data collected 
in the REPOSE trial, whereas the long-term model esti-
mated the lifetime costs and QALYs based mainly on 
the biomedical outcomes collected in the REPOSE trial. 
All modelling analyses took a lifetime time horizon, 
and all EEACT analyses took a 2-year (trial duration) 
time horizon. The prespecified primary analysis relates 
to the lifetime modelling, and as such, are reported in 
this paper. The methods and results of the EEACT are 
reported in online supplementary material A. In line with 
NICE guidance, all economic analyses took a National 
Health Service and personal social services perspective, 
and costs and QALY outcomes were discounted at 3.5%.13
the economic model
The Sheffield Type 1 Diabetes Policy Model version 1.3.2, 
henceforth ‘the model’, is an individual level simulation 
model used to estimate the lifetime costs and QALYs asso-
ciated with pump+DAFNE and MDI+DAFNE. The most 
recently published version of the model14 was updated 
using data collected in the REPOSE trial at 12-month 
and 24-month follow-up. Specifically, the level of HbA1c, 
risk of severe hypoglycaemia, risk of DKA and the prob-
ability that an individual would switch insulin delivery 
mechanism and costs related to the intervention (insulin 
and MDI consumables, diabetes related contacts with 
healthcare professionals, insulin pumps and the asso-
ciated consumables) were updated. Relevant literature 
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also informed the changes in HbA1c beyond the 2-year 
trial duration and the probability of death from end-stage 
renal disease (see online supplementary material B, page 
2) in both arms. The model examines disease progression 
over a lifetime using an annual time cycle. An individual’s 
HbA1c determines their risk of progression for all diabetic 
complications in the model, which include: nephropathy, 
neuropathy, retinopathy, macular oedema, myocardial 
infarction, stroke, heart failure, angina and severe hypo-
glycaemia and DKA. A higher HbA1c increases the risk of 
progression for all complications in the model. Individuals 
in the model are at risk of death from the incidence of: 
nephropathy, myocardial infarction, stroke, heart failure, 
angina and all-cause mortality. HbA1c indirectly effects 
mortality in the model, as the probability death does not 
differ by HbA1c; however, the risk of experiencing these 
events is higher for someone with a higher HbA1c. The 
model attaches utilities to health states and costs to 
events, allowing the calculation of costs and QALYs over 
a lifetime. Full details of how the model calculates the 
incidence of diabetes complications is provided in Heller 
et al (p. 104–106) and Thokala et al.14 15 The incremental 
cost-effectiveness ratio (ICER) calculated was compared 
with the £20 000 to £30 000 per QALY gained threshold 
used by NICE.13 In each model run, the life course of 
5000 individuals was simulated. This number of simu-
lated individuals was considered to be sufficiently robust 
for decision making (see online supplementary material 
B, page 1). All model analyses were conducted using 
SIMUL8 professional 2010.16
the clinical data
The details of the methods used in the REPOSE trial have 
been reported elsewhere.12 The eligibility criteria of the trial 
included adults with T1DM if they were eligible to receive a 
structured education course, did not have a clinical indica-
tion to receive a pump immediately, as determined by the 
investigator, or did not have a strong preference to receive a 
pump.12 The REPOSE trial was conducted in eight centres 
in England and Scotland, involving 267 individuals. Out 
of these 267 individuals, 260 had HbA1c data for at least 
one postbaseline follow-up visit (intention to treat (ITT) 
population) and 236 adhered to their randomised treat-
ment (per protocol population). Self-reported participant 
information, which includes the number of DKA events, 
EuroQol EQ-5D-3L, 12 item short form survey (SF-12) and 
resource use were collected at baseline, 6 months, 1 year 
and 2 years after attending DAFNE training. HbA1c, the 
primary endpoint, was measured at baseline and at these 
follow-up appointments. All inpatient admissions, the inci-
dence of severe hypoglycaemia and whether an individual 
switched insulin delivery method were collected on an 
ongoing basis. Information was collected on the staff time 
spent delivering precourse fitting sessions for individuals 
allocated to receive a pump. The cost of insulin pumps and 
associated consumables in routine practice, and the insulin 
pump consumables used by the REPOSE participants, were 
collected from seven of the eight trial centres.
the simulation cohort
To obtain the simulation cohort, participants’ REPOSE 
data (n=260) were sampled with replacement 5000 
times.17 This created a simulation cohort of 5000 individ-
uals for whom some would have missing baseline charac-
teristics. Each individual from REPOSE was included in 
the simulation cohort a median of 19 times (IQR 16–22). 
To obtain data values for these missing variables in the 
simulation cohort, two imputation procedures were used. 
A truncated regression procedure for missing continuous 
variables (baseline: total cholesterol, high-density lipo-
protein (HDL) cholesterol, systolic blood pressure and 
cost of insulin used in the year prior to baseline), in which 
variables were limited to positive values, and a Poisson 
procedure for missing categorical variables (gender). In 
the truncated regression imputation procedure, all char-
acteristics with complete data in the REPOSE trial popu-
lation were used as predictive covariates. In the Poisson 
imputation procedure, all characteristics with complete 
data in the REPOSE trial population and the imputed 
data for the continuous variables were used as predictive 
covariates. In both imputation procedures, a single impu-
tation was used. As this was preformed in the simulation 
cohort rather than the REPOSE data, the replications of 
the individuals in the simulation cohort had different 
data values if they had missing baseline data from the 
trial. Identical individuals were simulated in both model 
arms. A summary of the baseline characteristics and 
completeness of data for the 260 REPOSE participants in 
the ITT population and the 5000 individuals in the simu-
lation cohort are given in table 1.
the clinical effectiveness data
Statistical analyses of the REPOSE trial data were 
conducted to estimate treatment switching, HbA1c, severe 
hypoglycaemia and DKA. The main clinical results paper 
is available; however, it differs in this paper as it focuses 
on statistical in those people with a HbA1c greater than 
or equal to 58 mmol/mol (7.5%).18 Information on long-
term changes in HbA1c was obtained from the available 
literature and the REPOSE trial data. Unless otherwise 
stated, all statistical analyses were conducted using STATA 
V.13.1.19 Full details on the statistical methods used, the 
results and how the analyses were incorporated into the 
model are provided in online supplementary material B.
To estimate the incidence of treatment switching in 
the first and second year of the model, a time-to-event 
analysis was conducted using treatment switching as the 
event of interest. Kaplan-Meier curves were plotted, and 
parametric survival curves were fitted to the Kaplan-Meier 
curves.20 21 Separate parametric survival models were 
fitted to individuals randomised to pump+DAFNE and 
MDI+DAFNE. The goodness of fit of the parametric 
survival curves was assessed using the Akaike infor-
mation criterion, Bayesian information criterion and 
visual assessment of the fit of the parametric curves to 
the Kaplan-Meier curves at 1 and 2 years. As treatment 
switching was included in the model, it is important to 
 o
n
 16 M
ay 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-016766 on 7 April 2018. Downloaded from 
4 Pollard DJ, et al. BMJ Open 2018;8:e016766. doi:10.1136/bmjopen-2017-016766
Open Access 
Table 1 The baseline characteristics of REPOSE participants and the simulated cohort
Characteristic REPOSE trial population (n=260) Simulated cohort (n=5000)
Continuous variables mean (SD) (% of individuals with data prior to imputation)
  Baseline HbA1c (mmol/mol) 76.0 (18.6) (100) 75.9 (18.2) (100)
  Baseline HbA1c (%) 9.1 (1.7) (100) 9.1 (1.7) (100)
  Age (years) 40.4 (13.4) (100) 40.4 (13.3) (100)
  Diabetes duration (years) 18.0 (12.5) (100) 18.0 (12.3) (100)
  Triglycerides (mmol/mol) 1.4 (1.0) (100) 1.4 (0.9) (100)
  Total cholesterol (mmol/mol) 4.9 (0.9) (99.6) 4.9 (0.9) (99.7)
  HDL cholesterol (mmol/mol) 1.6 (0.4) (96.5) 1.6 (0.4) (96.4)
  LDL cholesterol (mmol/mol) 2.8 (0.9) (96.2) 2.7 (0.9) (96.1)
  Systolic blood pressure 131.4 (16.4) (98.8) 131.3 (16.0) (98.9)
  Baseline cost of insulin £357.24 (147.65) (94.8) £360.39 (157.92) (98.4)
  Baseline cost of diabetes-related contacts £561.61 (885.92) (100) £571.63 (928.92) (100)
Categorical variables n/N (percentage) (% of individuals prior to imputation)
  Gender
   Female 104/260 (40.0) (40.0) 1990/5000 (39.8) (39.3)
   Male 152/260 (58.5) (58.5) 2950/5000 (59.0) (59.3)
   Missing 4/260 (1.5) (1.5) 0/5000 (0.0) (1.4)
  Physical activity
   Low 67/260 (25.8) (25.8) 1266/5000 (25.3) (25.3)
   Medium 128/260 (49.2) (49.2) 2471/5000 (49.4) (49.4)
   High 65/260 (25.0) (25.0) 1263/5000 (25.3) (25.3)
  Smoking status
   Current 50/260 (19.2) (19.2) 951/5000 (19.2) (19.2)
   Former 67/260 (25.8) (25.8) 1325/5000 (26.3) (26.3)
   Never 143/260 (55.0) (55.0) 2724/5000 (54.5) (54.5)
  Race
   White 258/260 (99.2) (99.2) 4959/5000 (99.2) (99.2)
   Black 2/260 (0.8) (0.8) 41/5000 (0.8) (0.8)
  Nephropathy
   No complications 239/260 (91.9) (91.9) 4600/5000 (92.0) (92.0)
   Microalbuminuria 13/260 (5.0) (5.0) 234/5000 (4.7) (4.7)
   Macroalbuminuria 7/260 (2.7) (2.7) 152/5000 (3.0) (3.0)
   Dialysis or transplant 1/260 (0.4) (0.4) 14/5000 (0.4) (0.4)
  Neuropathy
   No complications 238/260 (91.5) (91.5) 4599/5000 (92.0) (92.0)
   Neuropathy or ulcers 22/260 (8.5) (8.5) 401/5000 (8.0) (8.0)
  Retinopathy
   No complications 145/260 (55.8) (55.8) 28/5000 (56.0) (56.0)
   Background diabetic retinopathy 91/260 (35.0) (35.0) 1740/5000 (34.8) (34.8)
   Proliferative diabetic retinopathy 24/260 (9.2) (9.2) 465/5000 (9.3) (9.3)
  Myocardial infarction
   No complications 255/260 (98.1) (98.1) 4896/5000 (97.9) (97.9)
   Myocardial infarction 5/260 (1.9) (1.9) 104/5000 (2.1) (2.1)
  Stroke
   No complications 259/260 (99.6) (99.6) 4983/5000 (99.7) (99.7)
   Stroke 1/260 (0.4) (0.4) 17/5000 (0.3) (0.3)
Continued
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adjust the modelled treatment effectiveness and cost of 
treatment for those individuals who switch. If individuals 
switched treatment, then their HbA1c was assumed to 
change as though they had been allocated to the other 
arm. No explicit effect of switching on the incidence rate 
ratio (IRR) associated with the model arms for either 
severe hypoglycaemia or DKA was included. However, due 
to the change in HbA1c associated with switching, individ-
uals who switched from pump to MDI were at a lower risk 
of severe hypoglycaemia and at a higher risk of DKA. The 
opposite was true for those individuals who switched from 
MDI to pump. In the base case analysis, the HbA1c effect 
of pump+DAFNE compared with MDI+DAFNE was esti-
mated in the per protocol population, as the people who 
switched treatment were excluded from this population.
To estimate each individual’s HbA1c in the model, a 
beta regression was fitted to the HbA1c data collected 
in REPOSE for all individuals in the per-protocol popu-
lation at the 1-year and 2-year follow-up.22 Bounds were 
placed on the beta regression so that HbA1c was between 
the clinically plausible bounds of 29 mmol/mol (4.8%) 
and 201 mmol/mol (20.5%), which were provided by 
two clinical experts in the REPOSE trial management 
group. Missing data were observed for HbA1c values in 
the per-protocol population at 6 months (2.1% missing), 
1 year (4.2% missing) and 2 years (4.2% missing). Full 
details on the imputation procedure used to account for 
the missing data and the specification of the beta regres-
sion are provided in online supplementary material B 
(see p. 8). The effects in a beta regression are not easily 
interpretable by themselves; however, information can be 
obtained on the direction of effect.
The expert opinion of clinical members involved in 
the literature review of clinical studies for the REPOSE 
trial was sought to identify studies with long-term data 
on HbA1c for the type of pumps used in the trial and 
people who used MDI after DAFNE. Three articles on the 
long-term trends in HbA1c for pump users23–25 and two 
articles on the long-term trends in HbA1c for MDI users 
post-DAFNE26 27 were used to estimate yearly changes in 
HbA1c for each model arm. The average annual increase 
in HbA1c was calculated for each study by calculating 
yearly increase in HbA1c between the lowest observed 
HbA1c value and the last follow-up point in the study 
where the sample size was greater than one quarter of the 
initial sample size. An SE could not be directly calculated, 
as we did not have access to the patient level data from the 
studies. Instead, data on the SD of the change in HbA1c 
between the 1-year and 2-year follow-ups specific to each 
REPOSE trial arm were used to inform the uncertainty in 
this parameter. These SDs were divided by the square root 
of the combined sample size of the studies used to inform 
the mean effect to estimate SE for this parameter.
Negative binomial regressions were used to estimate the 
risk of severe hypoglycaemia and DKA in the ITT popu-
lation of REPOSE using the Zellig package in R V.3.2.0. 
Negative binomial regressions were fitted separately to 
severe hypoglycaemia and DKA events and to the first and 
second years of follow-up data. The regressions fitted to 
the second year data were used to estimate the incidence 
of severe hypoglycaemia and DKA in all model time 
cycles, except for the first time cycle. This assumption was 
based on clinical expert opinion, which was confirmed 
by the trial management group, that the first 6 months of 
using a pump was associated with a learning period, and 
after this time, the incidence of severe hypoglycaemia 
and DKA would decrease.
Costs and utilities
The costs and health state utility values used for each 
health state in the model are provided in table 2 and 
table 3, respectively. All costs were reported in 2013/2014 
prices. Costs sourced from evidence in previous years 
were inflated to 2013/2014 prices using the hospital 
and community health services pay and prices index.28 
The cost of insulin and MDI consumables used, cost of 
diabetes related contacts with healthcare professionals 
and cost of the pump intervention costs were estimated 
separately for both year 1 and year 2 of the REPOSE 
trial. The unit cost of insulin and MDI consumables used 
was obtained from the British National Formulary and 
Health & Social Care Information Centre, the unit cost 
of diabetes related contacts were obtained from NHS 
reference costs and unit cost of an insulin pump (with its 
associated consumables) was obtained from a survey of 
the REPOSE trial sites.29–31 Table 2 part A shows the six 
regression formulae that estimate an individual’s annual 
cost for each of these components as a function of: their 
baseline HbA1c, which treatment they start the year on 
(MDI or pump), whether they switch treatment and also 
Characteristic REPOSE trial population (n=260) Simulated cohort (n=5000)
  Heart failure
   No complications 259/260 (99.6) (99.6) 4934/5000 (99.6) (99.6)
   Heart failure 1/260 (0.4) (0.4) 18/5000 (0.4) (0.4)
  Angina
   No complications 257/260 (98.9) (98.9) 4934/5000 (98.7) (98.7)
   Angina 3/260 (1.2) (1.2) 66/5000 (1.3) (1.3)
HDL, high-density lipoprotein; LDL, low-density lipoprotein; REPOSE, Relative Effectiveness of Pumps over Structured Education.
Table 1 Continued 
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the participants’ self-reported use of insulin and level of 
contact with healthcare professionals prior to recruitment 
to the trial. Details on how these parameters were used to 
estimate the costs in the model are provided in table 2.
scenario and subgroup analyses
For the base case, a probabilistic sensitivity anal-
ysis (PSA) was conducted where each parameter was 
sampled from its probability distribution, the results 
were recorded, the process was repeated 500 times and 
the averages from these 500 model runs were reported. 
This number of PSA runs was considered to be suffi-
cient to allow for robust decision making based on the 
model results (see online supplementary material B, 
page 1). All statistical models, except for the risks of 
severe hypoglycaemia and DKA, for which the outcomes 
were directly simulated in R V.3.2.0, were included in 
the model using a multivariate normal distribution.32 
The long-term changes in HbA1c were assumed to be 
distributed using independent normal distributions for 
each model arm. Deterministic scenario analyses were 
undertaken to assess the robustness of the results. The 
key scenario analyses for the model include: uncertainty 
in the estimates of treatment effectiveness, the timing 
of HbA1c changes in the model, the utility decrement 
Table 3 The base case utility parameters
Beta distribution
Health state for event Utility SE Alpha Beta Source
Baseline utility value
  Male with type 1 diabetes and no 
complications
0.866 0.010 947.79 146.90 Peasgood et al45
Gamma distribution
Disutility SE Alpha Beta Source
Complications or covariates
  Female with type 1 diabetes and no 
complications
0.0236 0.008 8.70 0.003 Peasgood et al45*
Adverse events‡
  Severe hypoglycaemia −0.002 −0.002 1 0.002 Peasgood et al45
  Diabetic ketoacidosis −0.0091 −0.01 0.83 0.01 Peasgood et al45*
Nephropathy§ 
  Microalbuminuria 0 Assumption
  Microalbuminuria −0.017 0.01 2.89 0.01 Coffey et al46
  ESRD −0.078 0.026 9 0.01 Coffey et al46
Neuropathy§ (applied to the history of events)
  Clinical neuropathy −0.055 0.01 30.25 0.002 Coffey et al46
  Clinically confirmed neuropathy −0.055 0.01 30.25 0.002 Coffey et al46
  Diabetic foot syndrome −0.1042 −0.119 0.77 0.14 Peasgood et al45
  PAD with amputation −0.1172 −0.055 4.54 0.03 Peasgood et al45*
Retinopathy§ (applied to the history of events)
  Background retinopathy −0.0544 −0.023 5.59 0.01 Peasgood et al45
  Proliferative retinopathy −0.0288 −0.026 1.23 0.02 Peasgood et al45
  Blindness −0.208 0.013 256 0.001 Coffey et al46
Cardiovascular§ (applied to the history of events)
  MI (first year) −0.065 0.03 4.69 0.01 Alva et al47
  MI (subsequent years) −0.057 0.03 3.61 0.02 Alva et al47
  Heart failure −0.101 0.032 9.96 0.010 Alva et al47
  Stroke −0.165 0.035 22.22 0.007 Alva et al47
  Angina −0.09 0.018 25 0.004 Clarke et al48†
*A parameter value was not available in the author’s preferred statistical model.
†Value is presented in table 5 as ischaemic heart disease.
‡These disutilites are applied transiently to the number of these events in each year.
§These disutilites are applied to the history of ever having had one of these events.
ESRD, end-stage renal disease; MI, myocardial infarction; PAD, peripheral arterial disease.
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for blindness (−0.26)33 and the cost of insulin pumps 
and insulin pump consumables.
A two-way deterministic threshold analysis was conducted 
to assess the HbA1c reduction and/or annual cost reduc-
tion necessary to potentially make pumps cost-effective 
in the UK. All threshold analysis runs were conducted 
deterministically. In this analysis, each individual’s HbA1c 
was estimated as though they received MDI. Then those 
individuals in the pump arm received a fixed change in 
HbA1c. This change in HbA1c was varied at 10 different 
values between −3.3mmol/mol (−0.3%) and −13.1mmol/
mol (−1.2%), and annual cost of insulin pumps were also 
varied between 100% of the observed cost in the REPOSE 
trial and 50% of the observed cost.
Deterministic subgroup analyses were conducted in the 
following populations:
1. baseline HbA1c <69 mmol/mol (8.5%)
2. baseline HbA1c ≥69 mmol/mol (8.5%)
3. baseline HbA1c ≥58 mmol/mol (7.5%)
4. 69 mmol/mol (8.5%) >baseline HbA1c ≥58 mmol/
mol (7.5%)
5. 80 mmol/mol (9.5%) >baseline HbA1c ≥69 mmol/
mol (8.5%)
6. baseline HbA1c ≥80 mmol/mol (9.5%)
7. all individuals in the per protocol population.
The subgroup analyses were conducted by resampling 
the simulation cohort from the individuals who met each 
of these criteria in the ITT population.
results
Clinical effectiveness data
Treatment switching
The analysis of treatment switching in the REPOSE trial 
suggested that an exponential curve provided the best fit 
to the data for individuals receiving pump+DAFNE and a 
Weibull curve provided the best fit for individuals in the 
MDI+DAFNE arm.
HbA1c
The results of the analysis of HbA1c data suggested that 
pump+DAFNE compared with MDI+DAFNE was associated 
with statistically insignificant HbA1c reductions in both year 
1 and in year 2. The analysis of the literature for long-term 
trends in HbA1c suggested that weighted average annual 
progression of HbA1c was +0.568 mmol/mol (+0.052%) per 
annum in the pump+DAFNE arm and +0.590 mmol/mol 
(+0.054%) per annum in the MDI+DAFNE arm. The esti-
mated standard errors for the long-term trends in HbA1c 
were of 0.627 mmol/mol (0.040%) for MDI+DAFNE and 
0.627 mmol/mol (0.057%) for pump+DAFNE.
These data produce a trace of HbA1c as in figure 1. 
The solid lines show the average HbA1c in the model for 
each year. The dotted lines show what the HbA1c would 
have been in each year, if a higher HbA1c did not have 
an indirect effect on the number of deaths in the model 
or treatment switching effects. The dashed line shows the 
number of people remaining alive in each year and is 
Figure 1 The trace of: (A) the mean HbA1c in each year of the model, (B) the mean HbA1c ignoring the effects of death and 
treatment switching, (C) the number of people alive in each year of the model in both arms over 30 years. DCCT,   Diabetes 
Control and Complications Trial; MDI, multiple daily injection.
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plotted on the secondary axis. As expected from the base 
case clinical results, the MDI+DAFNE arm has a higher 
HbA1c than the pumps+DAFNE arm, and this effect 
slightly increases over time
Severe hypoglycaemia and DKA
The results of the negative binomial models used to esti-
mate the incidence of DKA indicated that pump+DAFNE 
compared with MDI+DAFNE was associated with more 
DKA events in the first year (IRR 1.40, 95% CI 0.55 to 
3.58) but fewer events in year 2 (IRR 0.93, 95% CI 0.23 to 
3.69). The results of the negative binomial models used 
to estimate the incidence of severe hypoglycaemia indi-
cated that pump+DAFNE compared with MDI+DAFNE 
was associated with more severe hypoglycaemic events in 
year 1 (IRR 1.33, 95% CI 0.49 to 3.65) but fewer events in 
the second year (IRR 0.35, 95% CI 0.08 to 1.44).
base case results
Table 4 shows the base case results for the long-term 
cost-effectiveness analysis using the PSA. For the 
pump+DAFNE arm, the mean costs of the intervention 
are £42 124 discounted over the lifetime horizon, which 
compares with £19 829 for the MDI+DAFNE arm. This 
leads to an increase in intervention costs of £21 295 over a 
person’s lifetime. The QALYs lived, prior to applying the 
utility decrements associated with diabetic complications, 
in the pump+DAFNE arm is 13.91 QALYs compared with 
14.03 QALYs in the MDI+DAFNE arm, a difference of 0.11 
QALYs. The differential incidence of adverse events in the 
pump+DAFNE arm compared with the MDI+DAFNE arm 
leads to a lower costs (−£371) and higher QALYs (+0.00) 
per person. The reduced incidence of diabetic compli-
cations in the pump+DAFNE arm leads to lower costs 
(−£2070) and more QALYs (+0.01) per person. The net 
incremental lifetime cost of pump versus MDI is there-
fore estimated as £18 853 (95% CI £6175 to £31,645) 
per person. The net incremental QALY gain per person 
is 0.13 (95% CI −0.70 to +0.96) QALYs per person. The 
ICER associated with pump+DAFNE was £142 195 per 
QALY gained. This is considerable above the £30 000 
per QALY threshold, which is the higher limit at which 
NICE would usually consider interventions to be cost-ef-
fective.13 Figure 2A shows that this result is subject to a 
small degree of uncertainty, as in 14.0% of the PSA runs, 
pump+DAFNE would be considered as being cost-effec-
tive using the lower end of the range used by NICE.
scenario and subgroup analyses
The results of 11 scenario analyses are presented 
in figure 2B. None of the scenario analyses showed 
pump+DAFNE to be cost-effective versus MDI+DAFNE. 
The lowest ICER found (£31 747 per QALY gained) was 
for scenario 3 in which yearly cost of pumps and consum-
ables was halved.
The results of the two-way price and effectiveness 
threshold analysis are given in table 5. When the annual 
pump cost is assumed to be 100% of the prices observed 
in REPOSE, then the analysis shows that the reduction in 
HbA1c (for pump compared with MDI) would need to 
be 12.0 mmol/mol (1.1%) or more, for pump to have an 
ICER below £20 000 per QALY gained. When the annual 
cost is 25% lower, then a HbA1c reduction of more than 
7.7 mmol/mol (0.7%) would be needed to have an ICER 
below £20 000 per QALY gained. When the annual cost is 
halved, then a HbA1c reduction of 3.3 mmol/mol (0.3%) 
would be sufficient to have an ICER below £20 000 per 
QALY gained.
The result of the subgroup analyses are presented in 
figure 2C. Similarly to the scenario analysis, no subgroup 
was identified in which pump+DAFNE would be likely 
to be considered more cost-effective than MDI+DAFNE. 
The most cost-effective subgroup was those individuals 
with a baseline HbA1c greater than or equal to 80 mmol/
mol (9.5%), with an ICER of £96 394 per QALY gained 
versus MDI+DAFNE.
dIsCussIOn
This is the first study to examine the marginal benefits 
and cost-effectiveness of insulin delivered using pumps 
over MDI when both groups have had structured educa-
tion, in patients without an immediate clinical need for 
an insulin pump, as recommended by NICE. Our find-
ings show that providing pumps for this wider group of 
adults with T1DM would be unlikely to be considered 
cost-effective in the UK because the estimated ICER was 
just over £142 000, substantially higher than the £30 000 
per QALY upper limit often used by UK decision makers. 
This finding is also valid in all scenario and subgroup 
analyses examined. The threshold analysis indicates that 
if new insulin pump technology is developed and the 
costs are similar to current insulin pumps, a trial would 
have to demonstrate a HbA1c reduction in the region of 
11 mmol/mol (1.0%) to 13 mmol/mol (1.2%) compared 
with MDI+DAFNE for the new technology to be consid-
ered cost-effective in the UK for the population analysed 
in this study. Conversely, if insulin pump prices were 
halved, then reductions of only 3 mmol/mol compared 
with MDI are required.
The key strengths of this study are that it is based on 
a rigorously conducted cluster RCT with economic data 
directly collected during the study. Data completeness 
for the primary outcome was very high at 95%. The 
study uses an individual level simulation model of type 
1 diabetes disease progression over a lifetime horizon. 
The study does have limitations in terms of the evidence 
used to inform the long-term changes in HbA1c, which 
were based on five observational studies with follow-up 
ranging from 3.7 to 10 years, rather than trials with long 
follow-up periods. Also, as REPOSE is the first study to 
assess the effectiveness of pumps+DAFNE, the long-term 
evidence was based on observational studies of pumps 
in which the education component is likely to have 
been different from the DAFNE structured education 
provided in the REPOSE trial. Our PSA has incorporated 
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Table 4 Long-term cost-effectiveness analysis: base case results using probabilistic sensitivity analysis
MDI+DAFNE Pump+DAFNE Incremental
Mean lifetime discounted costs per person
  Intervention costs
   Insulin and MDI consumables £12 215 £5476 −£6740
   Diabetes-related contacts £5023 £6289 £1266
   Insulin pumps and pump consumables £2228 £28 967 £26 739
   DAFNE course £363 £392 £29
  Subtotal intervention costs £19 829 £41 124 £21 295
  Adverse event costs
   Severe hypoglycaemia £133 £41 −£92
   Diabetic ketoacidosis £1161 £882 −£279
  Subtotal cost of adverse events £1294 £922 −£371
  Long-term complication costs
   Nephropathy £40 786 £38 853 −£1933
   Neuropathy £1859 £1805 −£53
   Retinopathy+macular oedema £6365 £6263 −£102
   Myocardial infarction £1838 £1844 £6
   Heart failure £607 £609 £2
   Stroke £253 £254 £0
   Angina £1134 £1143 £8
  Total cost of long-term complications £52 841 £50 771 −£2070
  Total costs £73 964 £92 817 £18 853
(95% CI £6175 to £31 645)
Mean undiscounted life years per person
   Total life years 28.3181 28.7999 0.3790
(95% CI −2.7392 to 3.3403)
Mean discounted QALYs per person
   QALYs lived
   (excluding decrements due to complications)
13.9145 14.0292 0.1147
   QALYs lost due to adverse events
   Severe hypoglycaemia −0.0014 −0.0004 0.0009
   Diabetic ketoacidosis −0.0075 −0.0057 0.0018
  Subtotal QALYs due to adverse events −0.0088 −0.0061 0.0027
  QALYs lost due to complications
   Nephropathy −0.1853 −0.1792 0.0061
   Neuropathy −0.3092 −0.3010 0.0082
   Retinopathy+macular oedema −0.3316 −0.3293 0.0022
   Myocardial infarction −0.0528 −0.0532 −0.0004
   Heart failure −0.0385 −0.0387 −0.0002
   Stroke −0.0343 −0.0345 −0.0002
   Angina −0.0754 −0.0761 −0.0007
  Subtotal QALYs lost due to complications −1.0271 −1.0120 0.0152
  Total QALYs 12.8785 13.0111 0.1326
(95% CI −0.7087 to 0.9623)
Summary
  Total mean discounted costs per person £80 471 £99 337 £18 853
(95% CI £6175 to £31 645)
Continued
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uncertainty around these estimates. Second, the analysis 
of rates of DKA was based on self-reported occurrence 
of DKA in REPOSE (the same method as used in other 
recent trials of DAFNE Heller et al, chapter 8),14 rather 
than corroborated data on inpatient admissions that had 
a smaller number of events and could not be analysed 
statistically. Third, only one pump type was assessed in the 
trial, and some caution may be needed when considering 
extrapolating results to modern pumps with autosuspend 
features. Fourth, the results of the threshold analysis used 
to determine what the effectiveness of pumps would need 
to be considered cost-effective should be interpreted with 
some degree of caution for two reasons. First, we used 
a fixed HbA1c effect for every individual, rather than 
a method that accounts for heterogeneous treatment 
responses, and second, we assume switchers from MDI to 
pump get the fixed HbA1c reduction and switchers from 
pump to MDI get the same fixed HbA1c increase. In an 
MDI+DAFNE Pump+DAFNE Incremental
  Total mean undiscounted life years per person 28.3181 28.7999 0.3790
(95% CI −2.7392 to 3.3403)
  Total mean discounted QALYs per person 12.8785 13.0111 0.1326
(95% CI −0.7087 to 0.9623)
  ICER (£/QALY gained) £142 195
  Probability that pump+DAFNE is cost-effective at 
a threshold of £20 000 per QALY gained
14.0%
DAFNE, Dose Adjustment for Normal Eating; ICER, incremental cost-effectiveness ratio; MDI, multiple daily injections; 
pump, insulin pumps; QALY, quality-adjusted life year. 
Table 4 Continued 
Figure 2 The results of the economic analyses presented on the cost-effectiveness plane for: (A) the base case PSAs, (B) 
the results of the scenario analyses and (C) the results of the prespecified subgroup analyses. DCCT, Diabetes Control and 
Complications Trial; DKA, diabetic ketoacidosis; ICER, incremental cost-effectiveness ratio; MDI, multiple daily injection; PSA, 
probabilistic sensitivity analysis; QALYs, quality-adjusted life years.
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ITT analysis where switchers are included in their origi-
nally randomised arms, smaller HbA1c reductions than 
the ones in this analysis would likely lead to the same 
ICERs. Finally, as no one study could provide sufficient 
information on the disutility decrements associated with 
diabetic events for people with type 1 diabetes, the data 
come from disparate sources. This means that the magni-
tude of some events appears to be small compared with 
others. For example, end-stage renal disease has a utility 
decrement of −0.078, whereas heart failure has a higher 
decrement of −0.101.
A 2015 systematic review on the cost-effectiveness of 
insulin in various countries identified four studies from 
the UK, three of which presented an ICER.34 The base case 
ICERs in these three studies were £11 461, £25 648 and 
£37 712, which indicate that in two out of the three studies 
that pumps had an ICER within/below the threshold range 
usually used by NICE to determine the cost-effectiveness 
of technologies in the UK. However, most of the previous 
cost-effectiveness analyses used a reduction in Hba1c of 
10–13 mmol/mol (0.95%–1.2%) associated with pumps 
compared with MDI, based on the meta-analysis by Weiss-
berg-Benchell et al35, which included a mixture of RCTs 
and observational studies. This effect size is much larger 
than that observed in the REPOSE trial. Some of the effect 
size in the meta-analysis may be related to the education 
offered to people in the pump arms, which was not offered 
to people in the MDI arms and that MDI was not admin-
istered using both long-acting and short-acting analogue 
insulins in most studies included in the meta analysis. To 
our knowledge, REPOSE is the first large trial in adults with 
type one diabetes that provides evidence on pumps versus 
MDI (in which both long-acting and short-acting analogue 
insulins are used) that provides equivalent diabetes educa-
tion to both trial arms. As such, this economic analysis is the 
first cost-effectiveness analysis relevant to assessing whether 
pumps should be offered at the point when adults with 
T1DM in the UK are eligible to receive structured educa-
tion and do not have an immediate clinical need to receive 
a pump.
The key implication of this paper is that unless there is 
an immediate clinical need for using a pump, clinicians in 
the NHS should offer adults with T1DM a structured educa-
tion course of proven benefit, prior to considering pump 
therapy. This is because when pumps+DAFNE is compared 
with MDI+DAFNE, the incremental health benefits are rela-
tively small and the incremental lifetime costs are relatively 
high. This indicates that it would not be cost-effective to 
allow all adults with T1DM who are eligible for structured 
education, and have no clinical need for a pump, to also 
immediately receive an insulin pump.
A question not addressed by the REPOSE trial is 
whether pumps would be clinically effective and cost-ef-
fective in patients offered the technology at some point 
after having attended a structured education course. 
Generating this evidence would require a clinical study, 
which recruited participants who had previously received 
a structured education course of proven benefit and T
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randomising them to either continued MDI or pumps. 
While the current literature does provide some indica-
tion of which individuals may benefit from pumps, the 
clinical evidence informing these studies was not limited 
to those individuals who had first received structured 
education. This is important because the effectiveness of 
insulin pumps would be expected to differ in this group, 
with this being related to observed and unobserved 
patient characteristics. One particular hypothesis that 
we believe is worthwhile investigating is whether pumps 
should be used in the UK by those adults with T1DM 
who actively self-manage after attending a structured 
education course, but either have not achieved the NICE 
target HbA1c levels of less than or equal to 48 mmol/mol 
(6.5%) or who have problematic hypoglycaemia. Another 
important research question concerns the effectiveness 
and cost-effectiveness of support programmes posteduca-
tion, so that more adults with T1DM achieve glycaemic 
targets. The DAFNEplus NIHR programme grant, which 
will report in 2022, is developing and testing an adapted 
DAFNE course (based on previous research, behaviour 
change theory and technological support) and subse-
quent structured support to improve self-management 
and glucose control.36
In conclusion, the results indicate that it would not be 
cost-effective to offer pumps to all adults with T1DM in the 
UK, who are currently eligible to receive a structured educa-
tion course and do not have an immediate clinical need 
for a pump in the UK. Use of MDI+DAFNE is estimated to 
represent a better use of NHS resources than immediate 
commencement on a pump. Further research is required 
to improve the glycaemic control of adults with T1DM in 
the UK.
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